Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
[263 Pages Report] The global antiepileptic drugs market is expected to enjoy a valuation of US$ 17.3 Billion by the end of the year 2022, and further expand at a CAGR of 4.3% to reach a valuation of ~US$ 26.2 Billion by the year 2032. According to a recent, study by Future Market Insights, second-generation drugs are leading the market with a share of about 53.4% in the year 2021, within the global market.
Market Outlook:
Data Points | Market Insights |
---|---|
Market Value 2022 | US$ 17.3 Billion |
Market Value 2032 | US$ 26.2 Billion |
CAGR 2022-2032 | 4.3% |
Market Share of Top 5 Countries | 59.5% |
Key Market Players | Merck KGaA, Eisai Co., Ltd., AstraZeneca, Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Sanofi, Johnson & Johnson Service, Inc., and Dr. Reddy's Laboratories Ltd. |
Epilepsy is a widespread neurological disorder that affects over 70 million individuals worldwide. While there are many different forms of epileptic seizures, including non-convulsive, convulsive, focal, and generalized seizures, epilepsy is not a single disease or syndrome. Rather, it is a diverse group of conditions. Antiepileptic drug (AED) therapy is the main treatment for this disorder, which is characterized by recurrent seizures. If epilepsy is properly identified and treated, around two-thirds of people can manage their seizures.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for antiepileptic drugs was approximately 20.8% of the overall ~US$ 79.4 Billion of the global neurological disorder drugs market in 2021.
The sale of antiepileptic drugs expanded at a CAGR of 4.4% from 2012 to 2021.
The growth of the global market for anti-epileptic medications is anticipated to be fuelled by the rising number of drugs that regulatory bodies are approving. Over the projection period, it is anticipated that rising epilepsy prevalence would fuel market expansion in regions such as Europe.
For example, the European Journal of Neurology reported in 2015 that there were an estimated 0.9 million children and adolescents with active epilepsy, with a prevalence of 4.5-5.0 per 1,000, and that there were an estimated 130,000 new cases of epilepsy among children and adolescents in Europe each year, with an incidence rate of 70 per 100,000.
Furthermore, the market is anticipated to increase over the forecast period due to the rise in the number of inorganic growth strategies, such as partnerships by major firms.
Thus, owing to the aforementioned factors, the global antiepileptic drugs market is expected to grow at a CAGR of 4.3% during the forecast period from 2022 to 2032.
The International League Against Epilepsy (ILAE) refers to patients who do not respond to the combination of two carefully selected and administered anti-seizure medications (ASMs) as being "drug-resistant," which describes over 30% of epileptics who do not respond to widely known anti-seizure medications (ASMs).
In order to improve patient symptoms and their quality of life (QoL), as well as that of the caregivers, there is a great deal of responsibility placed on the research and development of novel pharmacological and non-pharmacological therapies with a focused approach.
A large clinical pipeline, as well as investigational studies for the development of novel antiepileptic drugs for pediatric and geriatric patients, will set the course for the opportunistic expansion of the overall antiepileptic drugs market.
The management of patients with epilepsy is hampered by the cognitive adverse effects of the medicine, disease, pharmacodynamics, and pharmacokinetics of antiepileptic drugs, all of which increase the likelihood of drug therapy complications in epileptic patients.
The majority of epileptic seizures can be controlled by making the most effective use of the AEDs that are currently available on the market. However, even with adequate therapy, roughly one-third of the cases remain uncontrolled. Because AEDs are complicated and epilepsy is a complex disease, drug therapy complications are frequent in people with epilepsy.
Patients who use AEDs may experience more drug interactions and drug toxicity due to the complexity of their medical conditions and prescriptions, which increases their chance of experiencing issues with their drug therapy and impairs their ability to control their seizures.
A drug therapy problem is an occurrence connected to medicine therapy that conflicts with the desired health outcome, either directly or indirectly. Drug therapy problems in patients with epilepsy are one of the major elements that influence the effectiveness of treatment and the reliability of medical care, thus hindering the market's overall growth.
The U.S. dominates the North American region with a total market share of about 76.7% in 2021 and is expected to continue to experience the same growth throughout the forecast period. This is owed to the presence of an advanced healthcare structure within the country, as well as the high prevalence of patients with epilepsy and related mood disorders.
China holds approximately 64.6% share of the East Asia market in 2021 and is projected to display growth at a lucrative CAGR of 5.3% during the forecast period. There are around 10 million epileptics in China. There is a significant "epilepsy treatment gap" in China, which is mostly a result of societal discrimination brought on by cultural views on epilepsy and shortcomings in healthcare delivery. This factor brings about an opportunity for expansion within the country, by the key players in the antiepileptic drugs market, over the forecast period.
Germany is set to exhibit growth at a CAGR of nearly 4.1% in the global antiepileptic drugs market during the forecast period. The majority of adult patients with focal epilepsies in a real-world clinical context in Germany take antiepileptic medications as monotherapy, according to the German Society for Epileptology. A significant factor influencing the growth of the nation's overall market for antiepileptic drugs is the high adoption of these drugs.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Second-generation antiepileptic drugs are expected to present high growth at a CAGR of 3.9% throughout the forecast period. According to a number of clinical trials, the use of second-generation AEDs reduces the number of epilepsy-related inpatient visits with patients with far more comorbidities. Neurologists and physicians near epilepsy centers prescribe second-generation antiepileptic drugs more frequently than primary care physicians, giving this segment traction in terms of growth.
The oral route of administration holds a share of around 62.2% in 2021, and this segment is expected to display gradual growth over the forecast period. For the chronic treatment of epilepsy, antiepileptic medications are frequently administered orally. Epilepsy therapy calls for the administration of drugs for both acute and chronic conditions using a variety of formulations.
Retail pharmacies hold the highest market share value of 46.1% during the year 2021. With increased penetration of the products into the market, the availability of antiepileptic drugs in retail pharmacies has further propelled the sales growth of the overall market. Moreover, with the growing worldwide prevalence of epilepsy, the retail pharmacies segment is set to expand at a lucrative CAGR of 4.6% throughout the forecast period.
The market is composed of a wide range of companies that are effectively competing for an increase in market share. They are either working with other businesses to achieve this goal or they are obtaining authorization from the government bodies to distribute the recently developed therapies to increase their geographic coverage.
Similarly, recent developments related to companies manufacturing antiepileptic drugs have been tracked by the team at Future Market Insights, which are available in the full report.
Attribute | Details |
---|---|
Historical Data Available for | 2012 to 2021 |
Forecast Period | 2022 to 2032 |
Market Analysis | US$ Million for Value |
Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
Key Market Segments Covered | Drug Generation, Route of Administration, Distribution Channel, and Region |
Key Companies Profiled |
|
Pricing | Available upon Request |
The global antiepileptic drugs market is set to reach a valuation of US$ 17.3 Bn in 2022 and is set to expand 1.5X over the next ten years.
The antiepileptic drugs market is expected to reach US$ 26.2 Bn by end of 2032 at a CAGR of 4.3%.
The growing geriatric population, rising burden of neurological diseases, and growing regulatory approvals for new products are some of the key trends in this market.
By region, North America holds the highest market share of around 43.6% by value, in 2021, in the global antiepileptic drugs market.
Europe accounts for about 23.4% of the global antiepileptic drugs market in 2021 and is projected to grow with a CAGR of 4.2% during the forecast period.
The US, China, Japan, India, and Germany are the top five countries, which are expected to drive demand in the antiepileptic drugs market.
Merck KGaA, Eisai Co., Ltd., AstraZeneca, Novartis AG, Abbott, Teva Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Sanofi, Johnson & Johnson Service, Inc., and Dr. Reddy's Laboratories Ltd, are some of the key players in the antiepileptic drugs industry.
From 2012 to 2021, the market for antiepileptic drugs expanded at the rate of 4.4%.
The antiepileptic drugs market in South Asia is expected to grow at 4.9% CAGR during the forecast period.
East Asia is set to present lucrative growth at a CAGR of 5.1% during the forecasted years.
1. Executive Summary | Antiepileptic Drugs Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Disease Epidemiology, by Region 4.2. Pipeline Assessment 4.3. Regulatory Landscape 4.4. Novel Drug Approvals 4.5. Patent Landscape 4.6. PESTEL Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Outlook 5.1.3. Global Pharmaceutical Industry Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Incidence of Mood Disorders 5.2.2. High Prevalence of Epilepsy 5.2.3. Growing Antiepileptic Drug Discovery and Development Activities 5.2.4. Drug Generation Licensing and Commercialization 5.2.5. Patent Protection 5.2.6. Regulatory Scenario 5.2.7. Reimbursement Scenario 5.2.8. Adoption of Antiepileptic Drugs by Hospital Pharmacies 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. By Drug Generation 6.1.2. By Route of Administration 6.1.3. By Distribution Channel 6.1.4. By Country 6.2. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis By Drug Generation 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Drug Generation, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Generation, 2022 to 2032 8.3.1. First Generation 8.3.2. Second Generation 8.3.3. Third Generation 8.4. Market Attractiveness Analysis By Drug Generation 9. Global Market Analysis By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis, By Route of Administration, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032 9.3.1. Oral 9.3.2. Intravenous 9.4. Market Attractiveness Analysis By Route of Administration 10. Global Market Analysis By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis, By Distribution Channel, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Online Pharmacies 10.3.4. Drug Stores 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 11.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Region 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 12.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. The USA 12.3.1.2. Canada 12.3.2. By Drug Generation 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug Generation 12.4.3. By Route of Administration 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Drivers and Restraints - Impact Analysis 12.7. Country-Level Analysis & Forecast 12.7.1. U.S. Market Analysis 12.7.1.1. Introduction 12.7.1.2. Market Analysis and Forecast by Market Taxonomy 12.7.1.2.1. By Drug Generation 12.7.1.2.2. By Route of Administration 12.7.1.2.3. By Distribution Channel 12.7.2. Canada Market Analysis 12.7.2.1. Introduction 12.7.2.2. Market Analysis and Forecast by Market Taxonomy 12.7.2.2.1. By Drug Generation 12.7.2.2.2. By Route of Administration 12.7.2.2.3. By Distribution Channel 13. Latin America Market Analysis 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 13.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Drug Generation 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Generation 13.4.3. By Route of Administration 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Drivers and Restraints - Impact Analysis 13.7. Country-Level Analysis & Forecast 13.7.1. Mexico Market Analysis 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Drug Generation 13.7.1.2.2. By Route of Administration 13.7.1.2.3. By Distribution Channel 13.7.2. Brazil Market Analysis 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Drug Generation 13.7.2.2.2. By Route of Administration 13.7.2.2.3. By Distribution Channel 13.7.3. Argentina Market Analysis 13.7.3.1. Introduction 13.7.3.2. Market Analysis and Forecast by Market Taxonomy 13.7.3.2.1. By Drug Generation 13.7.3.2.2. By Route of Administration 13.7.3.2.3. By Distribution Channel 14. Europe Market Analysis 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. The UK 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug Generation 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Generation 14.4.3. By Route of Administration 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country-Level Analysis & Forecast 14.7.1. Germany Market Analysis 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Drug Generation 14.7.1.2.2. By Route of Administration 14.7.1.2.3. By Distribution Channel 14.7.2. Italy Market Analysis 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Drug Generation 14.7.2.2.2. By Route of Administration 14.7.2.2.3. By Distribution Channel 14.7.3. France Market Analysis 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Drug Generation 14.7.3.2.2. By Route of Administration 14.7.3.2.3. By Distribution Channel 14.7.4. The UK Market Analysis 14.7.4.1. Introduction 14.7.4.2. Market Analysis and Forecast by Market Taxonomy 14.7.4.2.1. By Drug Generation 14.7.4.2.2. By Route of Administration 14.7.4.2.3. By Distribution Channel 14.7.5. Spain Market Analysis 14.7.5.1. Introduction 14.7.5.2. Market Analysis and Forecast by Market Taxonomy 14.7.5.2.1. By Drug Generation 14.7.5.2.2. By Route of Administration 14.7.5.2.3. By Distribution Channel 14.7.6. BENELUX Market Analysis 14.7.6.1. Introduction 14.7.6.2. Market Analysis and Forecast by Market Taxonomy 14.7.6.2.1. By Drug Generation 14.7.6.2.2. By Route of Administration 14.7.6.2.3. By Distribution Channel 14.7.7. Russia Market Analysis 14.7.7.1. Introduction 14.7.7.2. Market Analysis and Forecast by Market Taxonomy 14.7.7.2.1. By Drug Generation 14.7.7.2.2. By Route of Administration 14.7.7.2.3. By Distribution Channel 15. East Asia Market Analysis 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Generation 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Generation 15.4.3. By Route of Administration 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country-Level Analysis & Forecast 15.7.1. China Market Analysis 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Drug Generation 15.7.1.2.2. By Route of Administration 15.7.1.2.3. By Distribution Channel 15.7.2. Japan Market Analysis 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Drug Generation 15.7.2.2.2. By Route of Administration 15.7.2.2.3. By Distribution Channel 15.7.3. South Korea Market Analysis 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Drug Generation 15.7.3.2.2. By Route of Administration 15.7.3.2.3. By Distribution Channel 16. South Asia Market Analysis 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 16.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Thailand 16.3.1.5. Rest of South Asia 16.3.2. By Drug Generation 16.3.3. By Route of Administration 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Generation 16.4.3. By Route of Administration 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country-Level Analysis & Forecast 16.7.1. India Market Analysis 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Drug Generation 16.7.1.2.2. By Route of Administration 16.7.1.2.3. By Distribution Channel 16.7.2. Indonesia Market Analysis 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Drug Generation 16.7.2.2.2. By Route of Administration 16.7.2.2.3. By Distribution Channel 16.7.3. Malaysia Market Analysis 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Drug Generation 16.7.3.2.2. By Route of Administration 16.7.3.2.3. By Distribution Channel 16.7.4. Thailand Market Analysis 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Drug Generation 16.7.4.2.2. By Route of Administration 16.7.4.2.3. By Distribution Channel 17. Oceania Market Analysis 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 17.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Generation 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Generation 17.4.3. By Route of Administration 17.4.4. By Distribution Channel 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country-Level Analysis & Forecast 17.7.1. Australia Market Analysis 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Drug Generation 17.7.1.2.2. By Route of Administration 17.7.1.2.3. By Distribution Channel 17.7.2. New Zealand Market Analysis 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Drug Generation 17.7.2.2.2. By Route of Administration 17.7.2.2.3. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2012 to 2021 18.3. Current and Future Market Value (US$ Million) Analysis and Forecast, By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. North Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Drug Generation 18.3.3. By Route of Administration 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Generation 18.4.3. By Route of Administration 18.4.4. By Distribution Channel 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country-Level Analysis & Forecast 18.7.1. GCC Countries Market Analysis 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Drug Generation 18.7.1.2.2. By Route of Administration 18.7.1.2.3. By Distribution Channel 18.7.2. Turkey Market Analysis 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Drug Generation 18.7.2.2.2. By Route of Administration 18.7.2.2.3. By Distribution Channel 18.7.3. South Africa Market Analysis 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Drug Generation 18.7.3.2.2. By Route of Administration 18.7.3.2.3. By Distribution Channel 18.7.4. North Africa Market Analysis 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast by Market Taxonomy 18.7.4.2.1. By Drug Generation 18.7.4.2.2. By Route of Administration 18.7.4.2.3. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Merck KGaA 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Sales Footprint 20.3.1.4. Key Financials 20.3.1.5. SWOT Analysis 20.3.1.6. Strategy Overview 20.3.2. Eisai Co., Ltd. 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Sales Footprint 20.3.2.4. Key Financials 20.3.2.5. SWOT Analysis 20.3.2.6. Strategy Overview 20.3.3. AstraZeneca 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Sales Footprint 20.3.3.4. Key Financials 20.3.3.5. SWOT Analysis 20.3.3.6. Strategy Overview 20.3.4. Novartis AG 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Sales Footprint 20.3.4.4. Key Financials 20.3.4.5. SWOT Analysis 20.3.4.6. Strategy Overview 20.3.5. Abbott 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Sales Footprint 20.3.5.4. Key Financials 20.3.5.5. SWOT Analysis 20.3.5.6. Strategy Overview 20.3.6. Teva Pharmaceutical Industries Ltd. 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Sales Footprint 20.3.6.4. Key Financials 20.3.6.5. SWOT Analysis 20.3.6.6. Strategy Overview 20.3.7. Pfizer Inc. 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Sales Footprint 20.3.7.4. Key Financials 20.3.7.5. SWOT Analysis 20.3.7.6. Strategy Overview 20.3.8. GlaxoSmithKline plc 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Sales Footprint 20.3.8.4. Key Financials 20.3.8.5. SWOT Analysis 20.3.8.6. Strategy Overview 20.3.9. Sanofi 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Sales Footprint 20.3.9.4. Key Financials 20.3.9.5. SWOT Analysis 20.3.9.6. Strategy Overview 20.3.10. Johnson & Johnson Service, Inc. 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Sales Footprint 20.3.10.4. Key Financials 20.3.10.5. SWOT Analysis 20.3.10.6. Strategy Overview 20.3.11. Dr. Reddy's Laboratories Ltd. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Sales Footprint 20.3.11.4. Key Financials 20.3.11.5. SWOT Analysis 20.3.11.6. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 01: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 02: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032 by Route of Administration Table 03: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 04: Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region Table 05: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 06: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 07: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration Table 08: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 09: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 10: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration Table 12: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 13: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 14: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 15: Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Route of Administration Table 16: Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 17: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 18: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 19: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration Table 20: East Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 21: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 22: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 23: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Route of Administration Table 24: South Asia Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 25: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 26: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 27: Oceania Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Route of Administration Table 28: Oceania Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel Table 29: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Country Table 30: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Drug Generation Table 31: Middle East & Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2032by Route of Administration Table 32: Middle East & Africa Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2032, by Distribution Channel
Figure 01: Global Market Value (US$ Million) Analysis, 2012 to 2021 Figure 02: Global Market Forecast & Y-o-Y Growth, 2022 to 2032 Figure 03: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2021 to 2032 Figure 04: Global Market Value Share (%) Analysis 2022 and 2032, by Drug Generation Figure 05: Global Market Y-o-Y Growth (%) Analysis 2021-2032, by Drug Generation Figure 06: Global Market Attractiveness Analysis 2022 to 2032, by Drug Generation Figure 07: Global Market Value Share (%) Analysis 2022 and 2032, by Route of Administration Figure 08: Global Market Y-o-Y Growth (%) Analysis 2021-2032, by Route of Administration Figure 09: Global Market Attractiveness Analysis 2022 to 2032, by Route of Administration Figure 10: Global Market Value Share (%) Analysis 2022 and 2032, by Distribution Channel Figure 11: Global Market Y-o-Y Growth (%) Analysis 2021-2032, by Distribution Channel Figure 12: Global Market Attractiveness Analysis 2022 to 2032, by Distribution Channel Figure 13: Global Market Value Share (%) Analysis 2022 and 2032, by Region Figure 14: Global Market Y-o-Y Growth (%) Analysis 2021-2032, by Region Figure 15: Global Market Attractiveness Analysis 2022 to 2032, by Region Figure 16: North America Market Value (US$ Million) Analysis, 2012 to 2021 Figure 17: North America Market Value (US$ Million) Forecast, 2022-2032 Figure 18: North America Market Value Share, by Drug Generation (2022 E) Figure 19: North America Market Value Share, by Route of Administration (2022 E) Figure 20: North America Market Value Share, by Distribution Channel (2022 E) Figure 21: North America Market Value Share, by Country (2022 E) Figure 22: North America Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 23: North America Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 24: North America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 25: North America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 26: U.S. Market Value Proportion Analysis, 2021 Figure 27: Global Vs. U.S. Growth Comparison Figure 28: U.S. Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 29: U.S. Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 30: U.S. Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 31: Canada Market Value Proportion Analysis, 2021 Figure 32: Global Vs. Canada. Growth Comparison Figure 33: Canada Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 34: Canada Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 35: Canada Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 36: Latin America Market Value (US$ Million) Analysis, 2012 to 2021 Figure 37: Latin America Market Value (US$ Million) Forecast, 2022-2032 Figure 38: Latin America Market Value Share, by Drug Generation (2022 E) Figure 39: Latin America Market Value Share, by Route of Administration (2022 E) Figure 40: Latin America Market Value Share, by Distribution Channel (2022 E) Figure 41: Latin America Market Value Share, by Country (2022 E) Figure 42: Latin America Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 43: Latin America Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 44: Latin America Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 45: Latin America Market Attractiveness Analysis by Country, 2022 to 2032 Figure 46: Mexico Market Value Proportion Analysis, 2021 Figure 47: Global Vs Mexico Growth Comparison Figure 48: Mexico Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 49: Mexico Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 50: Mexico Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 51: Brazil Market Value Proportion Analysis, 2021 Figure 52: Global Vs. Brazil. Growth Comparison Figure 53: Brazil Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 54: Brazil Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 55: Brazil Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 56: Argentina Market Value Proportion Analysis, 2021 Figure 57: Global Vs Argentina Growth Comparison Figure 58: Argentina Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 59: Argentina Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 60: Argentina Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 61: Europe Market Value (US$ Million) Analysis, 2012 to 2021 Figure 62: Europe Market Value (US$ Million) Forecast, 2022-2032 Figure 63: Europe Market Value Share, by Drug Generation (2022 E) Figure 64: Europe Market Value Share, by Route of Administration (2022 E) Figure 65: Europe Market Value Share, by Distribution Channel (2022 E) Figure 66: Europe Market Value Share, by Country (2022 E) Figure 67: Europe Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 68: Europe Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 69: Europe Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 70: Europe Market Attractiveness Analysis by Country, 2022 to 2032 Figure 71: UK Market Value Proportion Analysis, 2021 Figure 72: Global Vs. UK Growth Comparison Figure 73: UK Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 74: UK Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 75: UK Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 76: Germany Market Value Proportion Analysis, 2021 Figure 77: Global Vs. Germany Growth Comparison Figure 78: Germany Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 79: Germany Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 80: Germany Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 81: Italy Market Value Proportion Analysis, 2021 Figure 82: Global Vs. Italy Growth Comparison Figure 83: Italy Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 84: Italy Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 85: Italy Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 86: France Market Value Proportion Analysis, 2021 Figure 87: Global Vs France Growth Comparison Figure 88: France Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 89: France Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 90: France Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 91: Spain Market Value Proportion Analysis, 2021 Figure 92: Global Vs Spain Growth Comparison Figure 93: Spain Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 94: Spain Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 95: Spain Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 96: Russia Market Value Proportion Analysis, 2021 Figure 97: Global Vs Russia Growth Comparison Figure 98: Russia Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 99: Russia Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 100: Russia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 101: BENELUX Market Value Proportion Analysis, 2021 Figure 102: Global Vs BENELUX Growth Comparison Figure 103: BENELUX Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 104: BENELUX Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 105: BENELUX Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 106: East Asia Market Value (US$ Million) Analysis, 2012 to 2021 Figure 107: East Asia Market Value (US$ Million) Forecast, 2022-2032 Figure 108: East Asia Market Value Share, by Drug Generation (2022 E) Figure 109: East Asia Market Value Share, by Route of Administration (2022 E) Figure 110: East Asia Market Value Share, by Distribution Channel (2022 E) Figure 111: East Asia Market Value Share, by Country (2022 E) Figure 112: East Asia Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 113: East Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 115: East Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 116: China Market Value Proportion Analysis, 2021 Figure 117: Global Vs. China Growth Comparison Figure 118: China Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 119: China Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 120: China Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 121: Japan Market Value Proportion Analysis, 2021 Figure 122: Global Vs. Japan Growth Comparison Figure 123: Japan Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 124: Japan Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 125: Japan Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 126: South Korea Market Value Proportion Analysis, 2021 Figure 127: Global Vs South Korea Growth Comparison Figure 128: South Korea Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 129: South Korea Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 130: South Korea Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 131: South Asia Market Value (US$ Million) Analysis, 2012 to 2021 Figure 132: South Asia Market Value (US$ Million) Forecast, 2022-2032 Figure 133: South Asia Market Value Share, by Drug Generation (2022 E) Figure 134: South Asia Market Value Share, by Route of Administration (2022 E) Figure 135: South Asia Market Value Share, by Distribution Channel (2022 E) Figure 136: South Asia Market Value Share, by Country (2022 E) Figure 137: South Asia Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 138: South Asia Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 139: South Asia Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 140: South Asia Market Attractiveness Analysis by Country, 2022 to 2032 Figure 141: India Market Value Proportion Analysis, 2021 Figure 142: Global Vs. India Growth Comparison Figure 143: India Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 144: India Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 145: India Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 146: Indonesia Market Value Proportion Analysis, 2021 Figure 147: Global Vs. Indonesia Growth Comparison Figure 148: Indonesia Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 149: Indonesia Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 150: Indonesia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 151: Malaysia Market Value Proportion Analysis, 2021 Figure 152: Global Vs. Malaysia Growth Comparison Figure 153: Malaysia Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 154: Malaysia Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 155: Malaysia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 156: Thailand Market Value Proportion Analysis, 2021 Figure 157: Global Vs. Thailand Growth Comparison Figure 158: Thailand Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 159: Thailand Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 160: Thailand Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 161: Oceania Market Value (US$ Million) Analysis, 2012 to 2021 Figure 162: Oceania Market Value (US$ Million) Forecast, 2022-2032 Figure 163: Oceania Market Value Share, by Drug Generation (2022 E) Figure 164: Oceania Market Value Share, by Route of Administration (2022 E) Figure 165: Oceania Market Value Share, by Distribution Channel (2022 E) Figure 166: Oceania Market Value Share, by Country (2022 E) Figure 167: Oceania Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 168: Oceania Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 169: Oceania Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 170: Oceania Market Attractiveness Analysis by Country, 2022 to 2032 Figure 171: Australia Market Value Proportion Analysis, 2021 Figure 172: Global Vs. Australia Growth Comparison Figure 173: Australia Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 174: Australia Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 175: Australia Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 176: New Zealand Market Value Proportion Analysis, 2021 Figure 177: Global Vs New Zealand Growth Comparison Figure 178: New Zealand Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 179: New Zealand Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 180: New Zealand Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 181: Middle East & Africa Market Value (US$ Million) Analysis, 2012 to 2021 Figure 182: Middle East & Africa Market Value (US$ Million) Forecast, 2022-2032 Figure 183: Middle East & Africa Market Value Share, by Drug Generation (2022 E) Figure 184: Middle East & Africa Market Value Share, by Route of Administration (2022 E) Figure 185: Middle East & Africa Market Value Share, by Distribution Channel (2022 E) Figure 186: Middle East & Africa Market Value Share, by Country (2022 E) Figure 187: Middle East & Africa Market Attractiveness Analysis by Drug Generation, 2022 to 2032 Figure 188: Middle East & Africa Market Attractiveness Analysis by Route of Administration, 2022 to 2032 Figure 189: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2022 to 2032 Figure 190: Middle East & Africa Market Attractiveness Analysis by Country, 2022 to 2032 Figure 191: GCC Countries Market Value Proportion Analysis, 2021 Figure 192: Global Vs GCC Countries Growth Comparison Figure 193: GCC Countries Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 194: GCC Countries Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 195: GCC Countries Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 196: Turkey Market Value Proportion Analysis, 2021 Figure 197: Global Vs. Turkey Growth Comparison Figure 198: Turkey Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 199: Turkey Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 200: Turkey Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 201: South Africa Market Value Proportion Analysis, 2021 Figure 202: Global Vs. South Africa Growth Comparison Figure 203: South Africa Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 204: South Africa Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 205: South Africa Market Share Analysis (%) by Distribution Channel, 2021 to 2032 Figure 206: North Africa Market Value Proportion Analysis, 2021 Figure 207: Global Vs North Africa Growth Comparison Figure 208: North Africa Market Share Analysis (%) by Drug Generation, 2021 to 2032 Figure 209: North Africa Market Share Analysis (%) by Route of Administration, 2021 to 2032 Figure 210: North Africa Market Share Analysis (%) by Distribution Channel, 2021 to 2032
Recommendations
Explore Healthcare Insights
View Reports